Joint Federal Committee

What Joint Federal Committee does

The Gemeinsamer Bundesausschuss (G-BA), translated as the Joint Federal Committee, is the highest statutory decision-making body of the joint self-governance in the German healthcare system, established under §91 of the Fifth Book of the German Social Code (SGB V). It determines which medical services, treatments, medications, and methods are covered by statutory health insurance (gesetzliche Krankenversicherung, GKV), with binding decisions affecting approximately 73 million insured persons — over 90% of the German population. Governance comprises stakeholder representatives from hospitals (Deutsche Krankenhausgesellschaft), statutory health insurance funds (GKV-Spitzenverband), physicians (Kassenärztliche Bundesvereinigung), dentists (Kassenzahnärztliche Bundesvereinigung), and patient representatives, with the Federal Ministry of Health (BMG) exercising supervisory authority and requiring non-objection before decisions take effect.

The G-BA's core outputs are regulatory rather than commercial: binding guidelines, directives, assessment procedures, and resolutions. These include Richtlinien (guidelines) such as the Mutterschafts-Richtlinie and Heilmittel-Richtlinie, benefit assessments under §35a SGB V for new medications, method evaluations under §137h SGB V for high-risk medical devices, and decisions on preventive care programs including cancer screening. The organization distributes outputs through a digital governance platform featuring a public decision database, livestreamed plenary sessions with archived recordings, an automated notification service (G-BA Infodienst), and an online ordering system for printed materials including the Mutterpass (maternity passport). The Innovationsausschuss (Innovation Committee), a sub-body, funds innovative healthcare delivery models and health services research.

The G-BA is funded exclusively through the statutory health insurance system via a system surcharge (Systemzuschlag) regulated under §91 SGB V, and does not generate commercial revenue. It is a governmental self-governance institution operating under public law, headquartered in Berlin at Gutenbergstraße 13 with a workforce of 51-100 employees. Strategic operational partners include IQWiG (commissioned for evidence evaluations) and IQTIG (commissioned for quality assurance), while the BMG provides statutory supervision.

Name

Joint Federal Committee

Legal name

Gemeinsamer Bundesausschuss

Website

https://g-ba.de

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

The Gemeinsamer Bundesausschuss (G-BA) is Germany's highest statutory decision-making body for joint self-governance in healthcare, issuing binding guidelines that determine which medical services, treatments, and medications are covered by statutory health insurance for approximately 73 million insured persons.

Ownership category

akta.pro rank

Product category

Healthcare Regulation

NAICS

Executive, Legislative, and Other General Government Support (921)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Economic Evaluation & Health Technology Assessment (Public Programs) (HLAJANAL)

akta.pro secondary industry

Monitoring, Evaluation, Reporting & Compliance (Grant Oversight) (HLAJALAN)

Keywords

• Healthcare regulation
• Clinical guidelines
• Benefit assessment
• Health technology assessment
• Statutory health insurance

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Others

Revenue model

1. Statutory Health Insurance System Funding: The G-BA is financed through a system surcharge (Systemzuschlag) collected from the statutory health insurance system. Funding is regulated under §91 SGB V and covers operational costs of the joint self-governance body.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Joint Federal Committee (G-BA) is the supreme decision-making body of the joint self-governance in the German healthcare system. It issues binding guidelines, directives, and assessment procedures that determine which medical services, medications, and treatments are covered by Germany's statutory health insurance (GKV), covering over 73 million beneficiaries. Its core outputs are Richtlinien (binding directives), Bewertungsverfahren (benefit and method assessment procedures), Versicherteninformationen (patient information), the Beschlüsse public resolutions database, the G-BA-Infodienst notification service, and the Innovationsausschuss innovation funding committee.

Product overview

Joint Federal Committee (Gemeinsamer Bundesausschuss - G-BA) is Germany's highest decision-making body for the joint self-governance in healthcare. It is not a traditional technology company but rather a regulatory institution that publishes binding guidelines, directives, and assessment procedures governing what healthcare services are covered by statutory health insurance. The core offerings include Richtlinien (Guidelines/Directives) such as the Mutterschafts-Richtlinie, Heilmittel-Richtlinie, and method evaluation procedures, along with informational services like Versicherteninformationen for patients, the G-BA-Infodienst for subscription updates, and a Beschlüsse database of resolutions. The Innovationsausschuss promotes innovative healthcare delivery models.

Differentiator

Problem solved

Functional benefit

Products and services

• Richtlinien (Guidelines/Directives) Binding directives and guidelines issued by G-BA that govern which healthcare services are covered by statutory health insurance, including maternity guidelines (Mutterschafts-Richtlinie), remedies guidelines (Heilmittel-Richtlinie), and method assessment guidelines. Targeted at contracted healthcare providers, statutory health insurance funds, and insured persons in Germany.
• Bewertungsverfahren (Assessment Procedures) Procedures for evaluating medical methods, drugs, and treatments to determine their coverage under German statutory health insurance, including Nutzenbewertung (benefit assessment) under §35a SGB V and Erprobung (trial assessment). Targeted at pharmaceutical manufacturers, medical device makers, and healthcare providers seeking coverage determinations.
• Versicherteninformationen (Insured Persons Information) Patient-facing information materials including brochures, guidelines, and educational documents about medical examinations, treatments, and screening programs covered by statutory health insurance. Targeted at insured persons (patients) and the general public in Germany, with materials available in Easy-to-Read language and multiple formats.
• G-BA-Infodienst (G-BA Info Service) Free subscription notification service providing daily updates on new G-BA publications including resolutions, press releases, and plenary session agendas. Targeted at healthcare stakeholders, journalists, and members of the public who want to track G-BA regulatory outputs.
• Bestellsystem (Ordering System) Online ordering system for G-BA publications and printed materials such as the Mutterpass (maternity passport) and Versicherteninformation brochures. Targeted at healthcare providers, patients, and the general public needing official G-BA printed materials.
• Beschlüsse (Resolutions Database) Publicly accessible online database of G-BA resolutions and decisions on healthcare coverage, medical methods, and insurance regulations. Targeted at healthcare providers, statutory health insurance funds, manufacturers, legal professionals, journalists, and the public.
• Innovationsausschuss (Innovation Committee) G-BA sub-committee responsible for promoting innovative healthcare delivery models and health services research projects through funding initiatives. Targeted at researchers, healthcare providers, and institutions developing new care delivery models in the German statutory health insurance system.

Quantifiable outcome

• Benefit assessments determine coverage of medications and treatments for 73+ million statutory insurance beneficiaries
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core.

• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)coreImplementation/ SI/ Consulting PartnerIQWiG is commissioned by G-BA to conduct systematic reviews, health technology assessments, and evidence evaluations for medical methods and medications. IQWiG produces the scientific foundations for G-BA benefit assessments.
• Kassenärztliche Bundesvereinigung (KBV)coreStrategic or Co-development PartnerThe National Association of Statutory Health Insurance Physicians is a key stakeholder in G-BA decisions, representing physicians in the joint self-governance body.
• GKV-SpitzenverbandcoreStrategic or Co-development PartnerThe National Association of Statutory Health Insurance Funds represents all health insurance providers in G-BA decision-making processes.
• Deutsche Krankenhausgesellschaft (DKG)coreStrategic or Co-development PartnerThe German Hospital Federation represents hospitals in G-BA decisions affecting inpatient care quality standards and requirements.
• Bundesministerium für Gesundheit (BMG)coreStrategic or Co-development PartnerThe Federal Ministry of Health exercises supervisory authority over G-BA. G-BA decisions require non-objection from BMG before taking effect.
• IQTIG (Institut für Qualitätssicherung und Transparenz im Gesundheitswesen)coreImplementation/ SI/ Consulting PartnerIQTIG is commissioned by G-BA to develop quality indicators and conduct external quality assurance procedures for inpatient care.
• Patient Representatives (Patientenbeteiligung)coreStrategic or Co-development PartnerPatient organizations participate in G-BA decision-making processes through designated patient representatives with speaking and voting rights.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Haute Autorité de Santé (HAS): HAS is France's independent public authority that assesses drugs, medical devices, and professional practices for reimbursement by French statutory health insurance. Like G-BA, it issues binding recommendations and produces HTA reports for a national single-payer system.
• Institute for Clinical and Economic Review (ICER): ICER is a US nonprofit that produces comparative effectiveness reports and value-based price benchmarks influencing US payer coverage. It performs HTA functions similar to G-BA's benefit assessments, though its recommendations are non-binding in a multi-payer system.
• Pharmaceutical Benefits Advisory Committee (PBAC): PBAC is the independent Australian expert body that recommends which medicines should be subsidized under the Pharmaceutical Benefits Scheme. It is directly comparable to G-BA's role in §35a SGB V drug benefit assessments and binding reimbursement recommendations.
• Agenzia Italiana del Farmaco (AIFA): AIFA is Italy's national medicines agency that handles pricing, reimbursement, and HTA for drugs reimbursed by the Servizio Sanitario Nazionale. Its reimbursement and pricing negotiations parallel G-BA's role in determining benefit and conditions of statutory coverage for pharmaceuticals.
• National Institute for Health and Care Excellence (NICE): NICE is the UK's HTA body that conducts technology appraisals and clinical guideline development for the NHS. It is the closest international analogue to G-BA's benefit assessment and method evaluation mandate, serving a similarly comprehensive single-payer population.
• Zorginstituut Nederland (ZIN): ZIN is the Dutch HTA body that advises on package coverage decisions in the basic health insurance package and assesses pharmaceutical value. It mirrors G-BA's role of evaluating effectiveness and cost-effectiveness to determine reimbursement in a mandatory national system.
• Canadian Agency for Drugs and Technologies in Health (CADTH): CADTH delivers HTA reports and reimbursement recommendations to Canadian public payers, performing drug and medical device assessments analogous to G-BA's §35a benefit assessments and method evaluations for a publicly funded health system.
• Tandvårds- och läkemedelsförmånsverket (TLV): TLV is Sweden's authority for pharmaceutical and dental care reimbursement decisions. It evaluates cost-effectiveness and value-based pricing for inclusion in the national drug benefits scheme, mirroring G-BA's economic evaluation function for the German statutory system.

Others

• Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG): IQWiG is commissioned by G-BA to produce the scientific evidence reports (systematic reviews, benefit assessments) that underlie G-BA's coverage decisions. It functions as G-BA's in-house scientific arm rather than as an independent peer, but operates in the same HTA methodology space.

Regional players

• Scottish Medicines Consortium (SMC): SMC assesses new medicines for use within NHS Scotland, producing HTA-based acceptance advice. While smaller in scope than G-BA, it operates the same kind of national HTA process with binding influence on a regional public payer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xbsky.app/profile/g-ba.de
• LinkedInlinkedin.com/company/gemeinsamer-bundesausschuss
• Instagraminstagram.com/gba.gesundheit
• Facebookfacebook.com/profile.php

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Joint Federal Committee